ALMDT.PA up 43.66% intraday on FDA clearance 09 Feb 2026: volume tells the story

The ALMDT.PA stock jumped to €6.17 intraday on 09 Feb 2026 after FDA clearance for a lung cancer AI tool, driving a heavy trading session on EURONEXT in Europe. Volume surged to 1,388,702.00 shares, well above the 357,588.00 average, and the price range hit a day low of €4.90 and a day high of €6.17. The move follows the company’s product approval news and a fresh wave of buy-side attention. We examine the price drivers, technical setup, valuation metrics, and model forecasts to show what traders should watch next.

ALMDT.PA stock intraday move and news drivers

Median Technologies SA (ALMDT.PA) rallied after FDA clearance of its lung cancer AI tool, which triggered the high-volume move on EURONEXT. The clearance is the primary catalyst and explains the 43.66% intraday gain and the spike in average daily volume.

Market reaction is concentrated in Europe and healthcare trading desks. For context, Median trades in EUR and has 36,657,592.00 shares outstanding and a market cap of €156,894,494.00. See the coverage of the approval for details source.

Price action, volume and technical snapshot

Price hit €6.17 after opening at €5.10, with a previous close of €4.30. Momentum indicators show an RSI near 52.34, ADX 42.50 indicating a strong intraday trend, and Bollinger upper band at €5.04.

Volume metrics confirm the high-volume mover status: 1,388,702.00 traded vs 357,588.00 average. On-balance volume reads 2,382,616.00 and MFI sits at 74.24, suggesting buyers dominated the session.

ALMDT.PA analysis: fundamentals and valuation

Median’s trailing EPS is -1.16 and trailing PE is -3.69, reflecting current losses. Key ratios show price-to-sales 6.73, EV/sales 8.22, and a current ratio of 0.35, highlighting liquidity pressure.

Revenue per share is 1.20 and free cash flow per share is -0.77. These fundamentals underline the stock’s binary risk: strong product news versus persistent negative earnings and tight working capital.

Technical and Meyka grade assessment

Meyka AI rates ALMDT.PA with a score out of 100: 69.04 — Grade B — HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technicals show short-term strength with an ADX 42.50 and ROC 23.03%, but a stretched MFI and tight liquidity argue for caution. We include this proprietary grade as an input, not advice.

Price targets, risks and trading considerations

Given the news-driven price jump, a near-term tactical price target is €7.50 on momentum. A prudent 12-month base case target is €3.50, with a downside risk target near €2.50 if commercial rollout stalls or cash metrics worsen.

Key risks include continued negative EPS, a low current ratio 0.35, and dependence on successful commercial adoption. Volume and follow-through over the next sessions will determine if the move sustains.

News flow, catalysts and sector context

The FDA clearance is the immediate catalyst and should trigger partnership and trial-readout interest. More regulatory approvals or commercial contracts would be positive catalysts.

Healthcare sector peers trade with higher average current ratios and PE multiples, so Median’s valuation will re-rate only with consistent revenue growth or margin improvement. Read the initial coverage and regional reports here source.

Final Thoughts

Intraday volume and the FDA clearance drove ALMDT.PA stock to €6.17 on 09 Feb 2026, confirming headline risk as the primary driver for this high-volume mover. Short-term momentum favors buyers, but fundamentals remain mixed: EPS -1.16, PE -3.69, price-to-sales 6.73, and a current ratio of 0.35. Meyka AI’s forecast model projects a yearly price of €2.91, implying -52.78% versus the current €6.17, and we flag that forecast as model-based and not guaranteed. Traders should watch volume continuity, follow-on FDA or commercial updates, and cash runway metrics. For active traders, consider a staged approach: capture short-term moves above €6.50 while using the €3.50 12-month base case and €2.50 downside as risk anchors. Meyka AI provides this analysis as an AI-powered market analysis platform to help frame decisions, not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.